楽天のお買い得が キーワードから即 検索できます。 楽天からのおすすめ商品
[November 4 AFP] about the vaccine for prevention of cervical cancer for which three inoculation was needed until now, The research findings of U.S. National Cancer Institute (National Cancer Institute) which validates at least one inoculation were released by the medicine magazine “Cancer Prevention Research (cancer prevention research)” on the 4th.
If connected with the simplification and the cost reduction of a vaccination, it is supposed that the increase in an inoculation rate by the younger age group is expectable.
Since the human papillomavirus (HPV) made into the main causes of ? cervix-of-uterus cancer is infected by a physical affair, a cervix-of-uterus cancer risk can be reduced by inoculating a HPV preventive vaccine into the inside of the boy girl who has not performed the physical affair yet.
However, according to research of the U.S. in 2012, it is about 30% which received three inoculation currently recommended among the 10th generation women in the U.S., and the boy is only only 7%.
The team of the cancer etiology and the genetics section of ? U.S. National Cancer Institute, It investigated about the clinical test using the vaccine for prevention of cervical cancer “Cervarix (Cervarix)” of English medicine manufacture major company Glaxo SmithKline (GlaxoSmithKline, GSK) done for about 7500 18?25-year-old women in Central America Costa Rica.
Although the candidate was recommended three all the members’ inoculation, for twenty percent of the woman, the number of times of inoculation was less than 3 times.
?, then a research team extracted and made the comparative analysis of the blood about the group of 78 women who have received the vaccination only once, and 120 persons’ group which was received twice and which 192 persons received 3 times.
Then, it is said that the antibody which receives the HPV16 type made into the main causes of cervix-of-uterus cancer in all three groups and 18 types has been checked.
? — the antibody of these existed in four years and in blood at the longest.
This is mostly in agreement with the term of validity of the HPV vaccine which the researcher considers.
In the group of one vaccination, although it was slightly low, if it is thought that it is mostly fixed through a period also with all the groups, and is “a continuous reaction”, the research team will also have pointed out ? antibody level.